{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:39:03Z","timestamp":1787791143647,"version":"build-2784847793"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T00:00:00Z","timestamp":1752278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T00:00:00Z","timestamp":1752278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-025-01207-9","type":"journal-article","created":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T12:57:08Z","timestamp":1752325028000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A live attenuated NS1-deficient vaccine candidate for cattle-origin influenza A (H5N1) clade 2.3.4.4.b viruses"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2878-5714","authenticated-orcid":false,"given":"Ahmed","family":"Mostafa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengjin","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramya S.","family":"Barre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Shivanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reagan","family":"Meredith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy N.","family":"Platt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruby A.","family":"Escobedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Bayoumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban M.","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasija","family":"Cupic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aitor","family":"Nogales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J. C.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adolfo","family":"Garc\u00eda-Sastre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7084-0804","authenticated-orcid":false,"given":"Luis","family":"Martinez-Sobrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,12]]},"reference":[{"key":"1207_CR1","doi-asserted-by":"publisher","first-page":"e02542","DOI":"10.1128\/mbio.02542-24","volume":"15","author":"A Mostafa","year":"2024","unstructured":"Mostafa, A. et al. Avian influenza A (H5N1) virus in dairy cattle: origin, evolution, and cross-species transmission. mBio 15, e02542\u201302524 (2024).","journal-title":"mBio"},{"key":"1207_CR2","unstructured":"CDC. H5 bird flu: current situation https:\/\/www.cdc.gov\/bird-flu\/situation-summary\/index.html (CDC, 2025)."},{"key":"1207_CR3","unstructured":"USDA. The occurrence of another highly pathogenic avian influenza (HPAI) spillover from wild birds into dairy cattle. (USDA, 2025)."},{"key":"1207_CR4","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1093\/cid\/ciz075","volume":"69","author":"MA Rolfes","year":"2019","unstructured":"Rolfes, M. A. et al. Effects of influenza vaccination in the United States during the 2017\u20132018 influenza season. Clin. Infect. Dis. 69, 1845\u20131853 (2019).","journal-title":"Clin. Infect. Dis."},{"key":"1207_CR5","doi-asserted-by":"publisher","first-page":"168","DOI":"10.15585\/mmwr.mm7308a3","volume":"73","author":"AM Frutos","year":"2024","unstructured":"Frutos, A. M. et al. Interim estimates of 2023-24 seasonal influenza vaccine effectiveness - United States. MMWR Morb. Mortal. Wkly Rep. 73, 168\u2013174 (2024).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"1207_CR6","unstructured":"Zeno, E. E. et al. Interim Effectiveness Estimates of 2024 Southern Hemisphere Influenza Vaccines in Preventing Influenza-Associated Hospitalization - REVELAC-i Network, Five South American Countries, March-July. 73, 861-868 http:\/\/sfxeu10.hosted.exlibrisgroup.com\/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi\/enc:UTF-8&ctx_tim=2025-02-16T14%3A54%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi\/fmt:kev:mtx:ctx&rfr_id=info:sid\/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi\/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Interim%20Effectiveness%20Estimates%20of%202024%20Southern%20Hemisphere%20Influenza%20Vaccines%20in%20Preventing%20Influenza-Associated%20Hospitalization%20-%20REVELAC-i%20Network,%20Five%20South%20American%20Countries,%20March-July%202024&rft.jtitle=MMWR.%20Morbidity%20and%20mortality%20weekly%20report&rft.au=Zeno,%20Erica%20E&rft.aucorp=REVELAC-i%20Network&rft.date=2024-10-03&rft.volume=73&rft.issue=39&rft.spage=861&rft.epage=868&rft.pages=861-868&rft.issn=0149-2195&rft.eissn=1545-861X&rft_id=info:doi\/10.15585\/mmwr.mm7339a1&rft_dat=%3Cgale_pubme%3EA812235072%3C\/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c439t-951f9a8858fb9bffcb5152588cd638c96412201e66b441b0d7e00a5397aefafc3%3C\/grp_id%3E%3Coa%3E%3C\/oa%3E%3Curl%3E%3C\/url%3E&rft_id=info:oai\/&rft_pqid=3113353099&rft_id=info:pmid\/39361525&rft_galeid=A812235072&rfr_iscdi=true (2024)."},{"key":"1207_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7305a1","volume":"73","author":"LA Grohskopf","year":"2024","unstructured":"Grohskopf, L. A., Ferdinands, J. M., Blanton, L. H., Broder, K. R. & Loehr, J. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024-25 Influenza Season. MMWR Recomm. Rep. 73, 1\u201325 (2024).","journal-title":"MMWR Recomm. Rep."},{"key":"1207_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00952-7","volume":"9","author":"R Rathnasinghe","year":"2024","unstructured":"Rathnasinghe, R. et al. Sequential immunization with chimeric hemagglutinin \u0394NS1 attenuated influenza vaccines induces broad humoral and cellular immunity. NPJ Vaccines 9, 169 (2024).","journal-title":"NPJ Vaccines"},{"key":"1207_CR9","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1086\/521304","volume":"196","author":"T Ichinohe","year":"2007","unstructured":"Ichinohe, T. et al. Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine. J. Infect. Dis. 196, 1313\u20131320 (2007).","journal-title":"J. Infect. Dis."},{"key":"1207_CR10","first-page":"e03721","volume":"16","author":"I Sanz-Mu\u00f1oz","year":"2024","unstructured":"Sanz-Mu\u00f1oz, I. et al. Are we serologically prepared against an avian influenza pandemic and could seasonal flu vaccines help us? mBio 16, e03721\u2013e03724 (2024).","journal-title":"mBio"},{"key":"1207_CR11","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.vaccine.2014.11.006","volume":"33","author":"L Rodgers","year":"2015","unstructured":"Rodgers, L., Pabst, L. J. & Chaves, S. S. Increasing uptake of live attenuated influenza vaccine among children in the United States, 2008\u20132014. Vaccine 33, 22\u201324 (2015).","journal-title":"Vaccine"},{"key":"1207_CR12","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1093\/cid\/ciz358","volume":"70","author":"L Matrajt","year":"2020","unstructured":"Matrajt, L., Halloran, M. E. & Antia, R. Successes and failures of the live-attenuated influenza vaccine: can we do better? Clin. Infect. Dis. 70, 1029\u20131037 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"1207_CR13","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1093\/infdis\/jiac068","volume":"227","author":"SA Moritzky","year":"2023","unstructured":"Moritzky, S. A. et al. The negative effect of preexisting immunity on influenza vaccine responses transcends the impact of vaccine formulation type and vaccination history. J. Infect. Dis. 227, 381\u2013390 (2023).","journal-title":"J. Infect. Dis."},{"key":"1207_CR14","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/s41587-022-01381-4","volume":"40","author":"L Si","year":"2022","unstructured":"Si, L. et al. Generation of a live attenuated influenza A vaccine by proteolysis targeting. Nat. Biotechnol. 40, 1370\u20131377 (2022).","journal-title":"Nat. Biotechnol."},{"key":"1207_CR15","doi-asserted-by":"crossref","unstructured":"Smith, A. et al. A live attenuated influenza vaccine elicits enhanced heterologous protection when the internal genes of the vaccine are matched to those of the challenge virus. J. Virol. 94, e01065 (2020)","DOI":"10.1128\/JVI.01065-19"},{"key":"1207_CR16","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S2352-4642(23)00225-0","volume":"7","author":"H Kildegaard","year":"2023","unstructured":"Kildegaard, H., Lund, L. C., Potteg\u00e5rd, A. & Stensballe, L. G. Effectiveness of the quadrivalent live attenuated influenza vaccine against influenza-related hospitalisations and morbidity among children aged 2 to 6 years in Denmark: a nationwide cohort study emulating a target trial. Lancet Child Adolesc. Health 7, 852\u2013862 (2023).","journal-title":"Lancet Child Adolesc. Health"},{"key":"1207_CR17","doi-asserted-by":"publisher","first-page":"6383","DOI":"10.1016\/j.vaccine.2008.08.046","volume":"26","author":"T Nolan","year":"2008","unstructured":"Nolan, T. et al. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children. Vaccine 26, 6383\u20136391 (2008).","journal-title":"Vaccine"},{"key":"1207_CR18","doi-asserted-by":"publisher","first-page":"e4028","DOI":"10.1371\/journal.pone.0004028","volume":"3","author":"T Chotpitayasunondh","year":"2008","unstructured":"Chotpitayasunondh, T., Thisyakorn, U., Pancharoen, C., Pepin, S. & Nougarede, N. Safety, humoral and cell mediated immune responses to two formulations of an inactivated, split-virion influenza A\/H5N1 vaccine in children. PLoS One 3, e4028 (2008).","journal-title":"PLoS One"},{"key":"1207_CR19","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1146\/annurev-virology-010320-044746","volume":"7","author":"S Gouma","year":"2020","unstructured":"Gouma, S., Anderson, E. M. & Hensley, S. E. Challenges of making effective influenza vaccines. Annu Rev. Virol. 7, 495\u2013512 (2020).","journal-title":"Annu Rev. Virol."},{"key":"1207_CR20","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/nrd4529","volume":"14","author":"F Krammer","year":"2015","unstructured":"Krammer, F. & Palese, P. Advances in the development of influenza virus vaccines. Nat. Rev. Drug Discov. 14, 167\u2013182 (2015).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1207_CR21","doi-asserted-by":"publisher","first-page":"526","DOI":"10.3389\/fmicb.2018.00526","volume":"9","author":"H Petersen","year":"2018","unstructured":"Petersen, H. et al. NS Segment of a 1918 influenza A virus-descendent enhances replication of H1N1pdm09 and virus-induced cellular immune response in mammalian and avian systems. Front. Microbiol. 9, 526 (2018).","journal-title":"Front. Microbiol."},{"key":"1207_CR22","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1099\/jgv.0.000542","volume":"97","author":"P Kanrai","year":"2016","unstructured":"Kanrai, P. et al. Identification of specific residues in avian influenza A virus NS1 that enhance viral replication and pathogenicity in mammalian systems. J. Gen. Virol. 97, 2135\u20132148 (2016).","journal-title":"J. Gen. Virol."},{"key":"1207_CR23","doi-asserted-by":"crossref","unstructured":"Khalil, A. M., Nogales, A., Mart\u00ednez-Sobrido, L. & Mostafa, A. Antiviral responses versus virus-induced cellular shutoff: a game of thrones between influenza A virus NS1 and SARS-CoV-2 Nsp1. Front. Cell. Infect. Microbiol. 14, 1357866 (2024)","DOI":"10.3389\/fcimb.2024.1357866"},{"key":"1207_CR24","doi-asserted-by":"crossref","unstructured":"Wang, P. et al. Generation of DelNS1 influenza viruses: a strategy for optimizing live attenuated influenza vaccines. mBio 10, e02180 (2019).","DOI":"10.1128\/mBio.02180-19"},{"key":"1207_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.954811","volume":"12","author":"A Nogales","year":"2022","unstructured":"Nogales, A., DeDiego, M. L. & Mart\u00ednez-Sobrido, L. Live attenuated influenza A virus vaccines with modified NS1 proteins for veterinary use. Front. Cell Infect. Microbiol. 12, 954811 (2022).","journal-title":"Front. Cell Infect. Microbiol."},{"key":"1207_CR26","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.coviro.2020.06.001","volume":"44","author":"L Martinez-Sobrido","year":"2020","unstructured":"Martinez-Sobrido, L., DeDiego, M. L. & Nogales, A. AGL2017-82570-RReverse genetics approaches for the development of new vaccines against influenza A virus infections. Curr. Opin. Virol. 44, 26\u201334 (2020).","journal-title":"Curr. Opin. Virol."},{"key":"1207_CR27","doi-asserted-by":"publisher","first-page":"10580","DOI":"10.1128\/JVI.01213-08","volume":"82","author":"R Hai","year":"2008","unstructured":"Hai, R. et al. Influenza B virus NS1-truncated mutants: live-attenuated vaccine approach. J. Virol. 82, 10580\u201310590 (2008).","journal-title":"J. Virol."},{"key":"1207_CR28","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2024.2447614","volume":"14","author":"A Mostafa","year":"2025","unstructured":"Mostafa, A. et al. Replication kinetics, pathogenicity and virus-induced cellular responses of cattle-origin influenza A(H5N1) isolates from Texas, United States. Emerg. Microbes Infect. 14, 2447614 (2025).","journal-title":"Emerg. Microbes Infect."},{"key":"1207_CR29","doi-asserted-by":"crossref","unstructured":"Steinig, E. & Coin, L. J. J. O. O. S. S. Nanoq: ultra-fast quality control for nanopore reads. J. Open Source Softw. 7, 2991 (2022).","DOI":"10.21105\/joss.02991"},{"key":"1207_CR30","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1093\/bioinformatics\/btw321","volume":"33","author":"L Salmela","year":"2017","unstructured":"Salmela, L., Walve, R., Rivals, E. & Ukkonen, E. Accurate self-correction of errors in long reads using de Bruijn graphs. Bioinformatics 33, 799\u2013806 (2017).","journal-title":"Bioinformatics"},{"key":"1207_CR31","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1093\/bioinformatics\/btw152","volume":"32","author":"H Li","year":"2016","unstructured":"Li, H. Minimap and miniasm: fast mapping and de novo assembly for noisy long sequences. Bioinformatics 32, 2103\u20132110 (2016).","journal-title":"Bioinformatics"},{"key":"1207_CR32","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. et al. The sequence alignment\/map format and SAMtools. Bioinformatics 25, 2078\u20132079 (2009).","journal-title":"Bioinformatics"},{"key":"1207_CR33","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1093\/bioinformatics\/btx699","volume":"34","author":"BS Pedersen","year":"2018","unstructured":"Pedersen, B. S. & Quinlan, A. R. Mosdepth: quick coverage calculation for genomes and exomes. Bioinformatics 34, 867\u2013868 (2018).","journal-title":"Bioinformatics"},{"key":"1207_CR34","doi-asserted-by":"publisher","first-page":"11189","DOI":"10.1093\/nar\/gks918","volume":"40","author":"A Wilm","year":"2012","unstructured":"Wilm, A. et al. LoFreq: a sequence-quality aware, ultra-sensitive variant caller for uncovering cell-population heterogeneity from high-throughput sequencing datasets. Nucleic Acids Res. 40, 11189\u201311201 (2012).","journal-title":"Nucleic Acids Res."},{"key":"1207_CR35","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.virol.2014.12.006","volume":"476","author":"A Nogales","year":"2015","unstructured":"Nogales, A., Baker, S. F. & Mart\u00ednez-Sobrido, L. Replication-competent influenza A viruses expressing a red fluorescent protein. Virology 476, 206\u2013216 (2015).","journal-title":"Virology"},{"key":"1207_CR36","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.virusres.2015.11.014","volume":"213","author":"A Nogales","year":"2016","unstructured":"Nogales, A. et al. Replication-competent fluorescent-expressing influenza B virus. Virus Res. 213, 69\u201381 (2016).","journal-title":"Virus Res."},{"key":"1207_CR37","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-Sobrido, L. & Garc\u00eda-Sastre, A. Generation of recombinant influenza virus from plasmid DNA. J. Vis. Exp. 42, 2057 (2010).","DOI":"10.3791\/2057"},{"key":"1207_CR38","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.jviromet.2013.07.021","volume":"193","author":"A Mostafa","year":"2013","unstructured":"Mostafa, A., Kanrai, P., Ziebuhr, J. & Pleschka, S. Improved dual promotor-driven reverse genetics system for influenza viruses. J. Virol. Methods 193, 603\u2013610 (2013).","journal-title":"J. Virol. Methods"},{"key":"1207_CR39","doi-asserted-by":"publisher","first-page":"e0116917","DOI":"10.1371\/journal.pone.0116917","volume":"10","author":"A Mostafa","year":"2015","unstructured":"Mostafa, A. et al. Efficient generation of recombinant influenza a viruses employing a new approach to overcome the genetic instability of HA segments. PLoS ONE 10, e0116917 (2015).","journal-title":"PLoS ONE"},{"key":"1207_CR40","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1099\/jgv.0.000390","volume":"97","author":"A Mostafa","year":"2016","unstructured":"Mostafa, A., Kanrai, P., Ziebuhr, J. & Pleschka, S. The PB1 segment of an influenza A virus H1N1 2009pdm isolate enhances the replication efficiency of specific influenza vaccine strains in cell culture and embryonated eggs. J. Gen. Virol. 97, 620\u2013631 (2016).","journal-title":"J. Gen. Virol."},{"key":"1207_CR41","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1093\/emboj\/17.1.288","volume":"17","author":"RE O\u2019Neill","year":"1998","unstructured":"O\u2019Neill, R. E., Talon, J. & Palese, P. The influenza virus NEP (NS2 protein) mediates the nuclear export of viral ribonucleoproteins. Embo J. 17, 288\u2013296 (1998).","journal-title":"Embo J."},{"key":"1207_CR42","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/978-1-0716-2453-1_19","volume":"2524","author":"K Chiem","year":"2022","unstructured":"Chiem, K., Nogales, A. & Martinez-Sobrido, L. Generation, characterization, and applications of influenza A reporter viruses. Methods Mol. Biol. 2524, 249\u2013268 (2022).","journal-title":"Methods Mol. Biol."},{"key":"1207_CR43","doi-asserted-by":"publisher","first-page":"3221","DOI":"10.4049\/jimmunol.1300504","volume":"191","author":"G Grodeland","year":"2013","unstructured":"Grodeland, G., Mjaaland, S., Roux, K. H., Fredriksen, A. B. & Bogen, B. DNA vaccine that targets hemagglutinin to MHC class II molecules rapidly induces antibody-mediated protection against influenza. J. Immunol. 191, 3221\u20133231 (2013).","journal-title":"J. Immunol."},{"key":"1207_CR44","doi-asserted-by":"publisher","first-page":"e0257521","DOI":"10.1371\/journal.pone.0257521","volume":"16","author":"C Delahaye","year":"2021","unstructured":"Delahaye, C. & Nicolas, J. Sequencing DNA with nanopores: troubles and biases. PLoS One 16, e0257521 (2021).","journal-title":"PLoS One"},{"key":"1207_CR45","doi-asserted-by":"publisher","first-page":"107","DOI":"10.4049\/jimmunol.2300343","volume":"212","author":"JL Lobby","year":"2024","unstructured":"Lobby, J. L., Danzy, S., Holmes, K. E., Lowen, A. C. & Kohlmeier, J. E. Both humoral and cellular immunity limit the ability of live attenuated influenza vaccines to promote T cell responses. J. Immunol. 212, 107\u2013116 (2024).","journal-title":"J. Immunol."},{"key":"1207_CR46","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.09.020421","volume":"9","author":"J Paget","year":"2019","unstructured":"Paget, J. et al. Global mortality associated with seasonal influenza epidemics: New burden estimates and predictors from the GLaMOR Project. J. Glob. Health 9, 020421 (2019).","journal-title":"J. Glob. Health"},{"key":"1207_CR47","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s11739-023-03456-9","volume":"19","author":"R Antonelli Incalzi","year":"2024","unstructured":"Antonelli Incalzi, R. et al. Influenza vaccination for elderly, vulnerable and high-risk subjects: a narrative review and expert opinion. Intern. Emerg. Med. 19, 619\u2013640 (2024).","journal-title":"Intern. Emerg. Med."},{"key":"1207_CR48","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.3389\/fimmu.2019.01605","volume":"10","author":"C Calzas","year":"2019","unstructured":"Calzas, C. & Chevalier, C. Innovative mucosal vaccine formulations against influenza A virus infections. Front. Immunol. 10, 1605 (2019).","journal-title":"Front. Immunol."},{"key":"1207_CR49","doi-asserted-by":"publisher","first-page":"8454","DOI":"10.1128\/JVI.00163-16","volume":"90","author":"B Zhou","year":"2016","unstructured":"Zhou, B. et al. Reversion of cold-adapted live attenuated influenza vaccine into a pathogenic virus. J. Virol. 90, 8454\u20138463 (2016).","journal-title":"J. Virol."},{"key":"1207_CR50","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1093\/infdis\/jir660","volume":"204","author":"T Banovic","year":"2011","unstructured":"Banovic, T. et al. Disseminated varicella infection caused by varicella vaccine strain in a child with low invariant natural killer T cells and diminished CD1d expression. J. Infect. Dis. 204, 1893\u20131901 (2011).","journal-title":"J. Infect. Dis."},{"key":"1207_CR51","unstructured":"WHO. Poliomyelitis: vaccine derived polio. (WHO, 2017)."},{"key":"1207_CR52","doi-asserted-by":"crossref","unstructured":"Bull, J. J. Evolutionary reversion of live viral vaccines: can genetic engineering subdue it? Virus Evol. 1, vev005 (2015)","DOI":"10.1093\/ve\/vev005"},{"key":"1207_CR53","doi-asserted-by":"publisher","first-page":"3691","DOI":"10.1016\/j.vaccine.2012.03.025","volume":"30","author":"B Zhou","year":"2012","unstructured":"Zhou, B. et al. Engineering temperature sensitive live attenuated influenza vaccines from emerging viruses. Vaccine 30, 3691\u20133702 (2012).","journal-title":"Vaccine"},{"key":"1207_CR54","doi-asserted-by":"publisher","first-page":"3580","DOI":"10.1016\/j.vaccine.2008.05.001","volume":"26","author":"L Wang","year":"2008","unstructured":"Wang, L. et al. Characterization of influenza virus variants with different sizes of the non-structural (NS) genes and their potential as a live influenza vaccine in poultry. Vaccine 26, 3580\u20133586 (2008).","journal-title":"Vaccine"},{"key":"1207_CR55","doi-asserted-by":"publisher","first-page":"e00519","DOI":"10.1128\/jvi.00519-22","volume":"96","author":"E Vandoorn","year":"2022","unstructured":"Vandoorn, E. et al. Pathobiology of an NS1-Truncated H3N2 Swine Influenza Virus Strain in Pigs. J. Virol. 96, e00519\u2013e00522 (2022).","journal-title":"J. Virol."},{"key":"1207_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.virol.2016.10.008","volume":"500","author":"A Nogales","year":"2017","unstructured":"Nogales, A. et al. Canine influenza viruses with modified NS1 proteins for the development of live-attenuated vaccines. Virology 500, 1\u201310 (2017).","journal-title":"Virology"},{"key":"1207_CR57","doi-asserted-by":"publisher","first-page":"8431","DOI":"10.1128\/JVI.79.13.8431-8439.2005","volume":"79","author":"M Quinlivan","year":"2005","unstructured":"Quinlivan, M. et al. Attenuation of equine influenza viruses through truncations of the NS1 protein. J. Virol. 79, 8431\u20138439 (2005).","journal-title":"J. Virol."},{"key":"1207_CR58","doi-asserted-by":"publisher","first-page":"4309","DOI":"10.1073\/pnas.070525997","volume":"97","author":"J Talon","year":"2000","unstructured":"Talon, J. et al. Influenza A and B viruses expressing altered NS1 proteins: a vaccine approach. Proc. Natl Acad. Sci. 97, 4309\u20134314 (2000).","journal-title":"Proc. Natl Acad. Sci."},{"key":"1207_CR59","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1128\/JVI.01920-08","volume":"83","author":"J Steel","year":"2009","unstructured":"Steel, J. et al. Live attenuated influenza viruses containing NS1 truncations as vaccine candidates against H5N1 highly pathogenic avian influenza. J. Virol. 83, 1742\u20131753 (2009).","journal-title":"J. Virol."},{"key":"1207_CR60","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00871-22","volume":"96","author":"J Bonifacio","year":"2022","unstructured":"Bonifacio, J. et al. Optimizing the Live attenuated influenza A vaccine backbone for high-risk patient groups. J. Virol. 96, e0087122 (2022).","journal-title":"J. Virol."},{"key":"1207_CR61","doi-asserted-by":"publisher","first-page":"3996","DOI":"10.1128\/JVI.74.9.3996-4003.2000","volume":"74","author":"GE Price","year":"2000","unstructured":"Price, G. E., Gaszewska-Mastarlarz, A. & Moskophidis, D. The role of alpha\/beta and gamma interferons in development of immunity to influenza A virus in mice. J. Virol. 74, 3996\u20134003 (2000).","journal-title":"J. Virol."},{"key":"1207_CR62","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.714","volume":"5","author":"R Wang","year":"2024","unstructured":"Wang, R. et al. The interaction of innate immune and adaptive immune system. MedComm 5, e714 (2024).","journal-title":"MedComm"},{"key":"1207_CR63","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1159\/000508379","volume":"12","author":"W Wu","year":"2020","unstructured":"Wu, W. & Metcalf, J. P. The role of type I IFNs in influenza: antiviral superheroes or immunopathogenic villains? J. Innate Immun. 12, 437\u2013447 (2020).","journal-title":"J. Innate Immun."},{"key":"1207_CR64","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nri3787","volume":"15","author":"F McNab","year":"2015","unstructured":"McNab, F., Mayer-Barber, K., Sher, A., Wack, A. & O\u2019Garra, A. Type I interferons in infectious disease. Nat. Rev. Immunol. 15, 87\u2013103 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"1207_CR65","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0065-2776(07)96002-2","volume":"96","author":"JR Schoenborn","year":"2007","unstructured":"Schoenborn, J. R. & Wilson, C. B. Regulation of interferon-gamma during innate and adaptive immune responses. Adv. Immunol. 96, 41\u2013101 (2007).","journal-title":"Adv. Immunol."},{"key":"1207_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4864","volume":"5","author":"S Davidson","year":"2014","unstructured":"Davidson, S., Crotta, S., McCabe, T. M. & Wack, A. Pathogenic potential of interferon \u03b1\u03b2 in acute influenza infection. Nat. Commun. 5, 3864 (2014).","journal-title":"Nat. Commun."},{"key":"1207_CR67","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/mi.2012.2","volume":"5","author":"O Dienz","year":"2012","unstructured":"Dienz, O. et al. Essential role of IL-6 in protection against H1N1 influenza virus by promoting neutrophil survival in the lung. Mucosal Immunol. 5, 258\u2013266 (2012).","journal-title":"Mucosal Immunol."},{"key":"1207_CR68","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1002\/eji.201243018","volume":"43","author":"SN Lauder","year":"2013","unstructured":"Lauder, S. N. et al. Interleukin-6 limits influenza-induced inflammation and protects against fatal lung pathology. Eur. J. Immunol. 43, 2613\u20132625 (2013).","journal-title":"Eur. J. Immunol."},{"key":"1207_CR69","doi-asserted-by":"crossref","unstructured":"Piattini, F., Sidiropoulos, N. D., Berest, I. & Kopf, M. IL-6 mediates defense against influenza virus by promoting protective antibody responses but not innate inflammation. Mucosal Immunol. 18, 596\u2013606 (2025)","DOI":"10.1016\/j.mucimm.2025.02.001"},{"key":"1207_CR70","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1084\/jem.20160417","volume":"213","author":"R Yang","year":"2016","unstructured":"Yang, R. et al. IL-6 promotes the differentiation of a subset of naive CD8+ T cells into IL-21\u2013producing B helper CD8+ T cells. J. Exp. Med. 213, 2281\u20132291 (2016).","journal-title":"J. Exp. Med."},{"key":"1207_CR71","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1111\/j.1523-1755.2002.kid572.x","volume":"62","author":"U Haberstroh","year":"2002","unstructured":"Haberstroh, U. et al. Expression of the chemokines MCP-1\/CCL2 and RANTES\/CCL5 is differentially regulated by infiltrating inflammatory cells. Kidney Int. 62, 1264\u20131276 (2002).","journal-title":"Kidney Int."},{"key":"1207_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.549020","volume":"11","author":"T Silva","year":"2021","unstructured":"Silva, T. et al. The Chemokine CCL5 inhibits the replication of influenza A virus through SAMHD1 modulation. Front. Cell Infect. Microbiol. 11, 549020 (2021).","journal-title":"Front. Cell Infect. Microbiol."},{"key":"1207_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/cti.2017.8","volume":"6","author":"S Wolf","year":"2017","unstructured":"Wolf, S., Johnson, S., Perwitasari, O., Mahalingam, S. & Tripp, R. A. Targeting the pro-inflammatory factor CCL2 (MCP-1) with Bindarit for influenza A (H7N9) treatment. Clin. Transl. Immunol. 6, e135 (2017).","journal-title":"Clin. Transl. Immunol."},{"key":"1207_CR74","doi-asserted-by":"publisher","first-page":"587","DOI":"10.3389\/fmicb.2017.00587","volume":"8","author":"C Lai","year":"2017","unstructured":"Lai, C., et al. C-C motif chemokine ligand 2 (CCL2) mediates acute lung injury induced by lethal influenza H7N9 virus. Front. Microbiol. 8, 587 (2017).","journal-title":"Front. Microbiol."},{"key":"1207_CR75","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.4049\/jimmunol.182.2.1088","volume":"182","author":"KPY Hui","year":"2009","unstructured":"Hui, K. P. Y. et al. Induction of proinflammatory cytokines in primary human macrophages by influenza A virus (H5N1) is selectively regulated by ifn regulatory factor 3 and p38 MAPK1. J. Immunol. 182, 1088\u20131098 (2009).","journal-title":"J. Immunol."},{"key":"1207_CR76","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s00011-016-0996-0","volume":"66","author":"LP Tavares","year":"2017","unstructured":"Tavares, L. P., Teixeira, M. M. & Garcia, C. C. The inflammatory response triggered by Influenza virus: a two edged sword. Inflamm. Res. 66, 283\u2013302 (2017).","journal-title":"Inflamm. Res."},{"key":"1207_CR77","doi-asserted-by":"crossref","unstructured":"Phipps, K. L. et al. Seasonal H3N2 and 2009 pandemic H1N1 influenza A viruses reassort efficiently but produce attenuated progeny. J. Virol. 91, e00830 (2017).","DOI":"10.1128\/JVI.00830-17"},{"key":"1207_CR78","doi-asserted-by":"crossref","unstructured":"Nogales, A. et al. Replication-competent \u0394NS1 influenza A viruses expressing reporter genes. Viruses 13, 698 (2021)","DOI":"10.3390\/v13040698"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01207-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01207-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01207-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T20:01:33Z","timestamp":1778270493000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01207-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,12]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1207"],"URL":"https:\/\/doi.org\/10.1038\/s41541-025-01207-9","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,12]]},"assertion":[{"value":"29 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Influenza research conducted in the L.M.-S. laboratory was not supported by CRIPT or CEIRR funding. In this article L.M-S which was included in the acknowledgement section and associated with CEIRR funding should be removed.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The A.G.-S. laboratory has received research support from GSK, Pfizer, Senhwa Biosciences, Kenall Manufacturing, Blade Therapeutics, Avimex, Johnson & Johnson, Dynavax, 7Hills Pharma, Pharmamar, ImmunityBio, Accurius, Nanocomposix, Hexamer, N-fold LLC, Model Medicines, Atea Pharma, Applied Biological Laboratories and Merck. A.G.-S. has consulting agreements for the following companies involving cash and\/or stock: Castlevax, Amovir, Vivaldi Biosciences, Contrafect, 7Hills Pharma, Avimex, Pagoda, Accurius, Esperovax, Applied Biological Laboratories, Pharmamar, CureLab Oncology, CureLab Veterinary, Synairgen, Paratus, Pfizer and Prosetta. A.G.-S. has been an invited speaker in meeting events organized by Seqirus, Janssen, Abbott, Astrazeneca and NovavaxA.G.-S. is inventor on patents and patent applications on the use of antivirals and vaccines for the treatment and prevention of virus infections and cancer, owned by the Icahn School of Medicine at Mount Sinai, New York. All other authors declare no commercial or financial conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"151"}}